Tumor Biology

, Volume 36, Issue 12, pp 9295–9301 | Cite as

Interaction analysis of IL-12A and IL-12B polymorphisms with the risk of colorectal cancer

  • Ruifen Sun
  • Fu Jia
  • Yundan Liang
  • Lijuan Li
  • Peng Bai
  • Fang Yuan
  • Linbo Gao
  • Lin Zhang
Research Article


IL-12 is an antitumor cytokine with functions of inhibiting tumor growth, invasion, and metastasis, indicating that IL-12 is a promising candidate for cancer treatment. The aim of this study was to investigate the association of IL-12A rs568408, IL-12A rs2243115, and IL-12B rs3212227 with the susceptibility to colorectal cancer (CRC). Two hundred and fifty-seven histopathologically confirmed CRC patients and 236 age- and gender-matched controls were enrolled. The three polymorphisms were genotyped using a polymerase chain reaction–restriction fragment length polymorphism assay. We found that the IL-12A rs568408 AG/AA genotypes were associated with an increased risk of CRC with an adjusted odds ratio (OR) of 1.66 (95 % confidence interval (CI), 1.11–2.48). Stratified analyses showed that patients carrying the IL-12B rs3212227AC/CC genotypes had a 1.97-fold increased risk of tumor metastasis (OR = 1.97; 95 % CI, 1.04–3.70). Gene–gene interaction analysis showed that subjects carrying the IL-12A rs568408AG/AA and IL-12B rs3212227AA genotypes had a 2.40-fold increased risk of CRC (OR = 2.40; 95 % CI, 1.14–5.07) and individuals carrying the IL-12A rs568408AG/AA and IL-12B rs3212227AC/CC genotypes had a 1.93-fold increased risk of CRC (OR = 1.93; 95 % CI, 1.10–3.41). These findings indicate that IL-12A rs568408 and IL-12B rs3212227 may be related to the development of CRC.


Interleukin-12A Interleukin-12B Polymorphism Colorectal cancer 



This study was funded by the National Natural Science Foundation of China (Nos. 81302149 and 81202387), the Ph.D. Programs Foundation of Ministry of Education of China (No. 20130181120011), Distinguished Young Scientist of Sichuan University (No. 2013SCU04A38), and the Science & Technology Pillar Program of Sichuan Province (Nos. 2014SZ0001 and 2013JY0013).

Conflicts of interest


Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74. 74 e1-4, quiz e12-3.CrossRefPubMedGoogle Scholar
  3. 3.
    Bae SI, Kim YS. Colon cancer screening and surveillance in inflammatory bowel disease. Clin Endosc. 2014;47(6):509–15.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis. 2010;28(4-5):619–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Herszenyi L, Barabas L, Miheller P, Tulassay Z. Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. Dig Dis. 2015;33(1):52–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Basavaraju U, Shebl FM, Palmer AJ, Berry S, Hold GL, El-Omar EM, et al. Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland. Eur J Cancer Prev. 2015;24(4):296–304.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, et al. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother. 2015;64(2):181–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2009;30(2):295–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63(5):419–35.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Stanilov NS, Miteva LD, Dobreva ZG, Jovchev JP, Cirovski GM, Stanilova SA. Monocytes expression of IL-12 related and IL-10 genes in association with development of colorectal cancer. Mol Biol Rep. 2012;39(12):10895–902.CrossRefPubMedGoogle Scholar
  11. 11.
    Nakayama Y, Sako T, Shibao K, Onitsuka K, Nagashima N, Hirata K, et al. Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer. Anticancer Res. 2000;20(6A):4097–102.PubMedGoogle Scholar
  12. 12.
    McRae BL, Semnani RT, Hayes MP, van Seventer GA, Type I. IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol. 1998;160(9):4298–304.PubMedGoogle Scholar
  13. 13.
    Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155(2):537–47.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, et al. Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS One. 2011;6(5), e19664.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yin XL, Wang N, Wei X, Xie GF, Li JJ, Liang HJ. Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice. Cancer Lett. 2012;322(1):92–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol. 2002;2(6):337–49.CrossRefPubMedGoogle Scholar
  17. 17.
    Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 1999;6(6):514–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Hiscox S, Hallett MB, Puntis MC, Jiang WG. Inhibition of cancer cell motility and invasion by interleukin-12. Clin Exp Metastasis. 1995;13(5):396–404.CrossRefPubMedGoogle Scholar
  19. 19.
    Shen F, Li JL, Cai WS, Zhu GH, Gu WL, Jia L, et al. Interleukin-12 prevents colorectal cancer liver metastases in mice. Onco Targets Ther. 2013;6:523–6.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Malvicini M, Rizzo M, Alaniz L, Pinero F, Garcia M, Atorrasagasti C, et al. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res. 2009;15(23):7256–65.CrossRefPubMedGoogle Scholar
  21. 21.
    Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 1998;5(10):1400–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut. 2011;60(3):341–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999;10(5):697–709.CrossRefPubMedGoogle Scholar
  24. 24.
    Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009;15(1):400–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Han SS, Cho EY, Lee TS, Kim JW, Park NH, Song YS, et al. Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical cancer in Korean women. Eur J Obstet Gynecol Reprod Biol. 2008;140(1):71–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Roszak A, Mostowska A, Sowinska A, Lianeri M, Jagodzinski PP. Contribution of IL12A and IL12B polymorphisms to the risk of cervical cancer. Pathol Oncol Res. 2012;18(4):997–1002.CrossRefPubMedGoogle Scholar
  27. 27.
    Navaglia F, Basso D, Zambon CF, Ponzano E, Caenazzo L, Gallo N, et al. Interleukin 12 gene polymorphisms enhance gastric cancer risk in H pylori infected individuals. J Med Genet. 2005;42(6):503–10.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yin J, Wang X, Wei J, Wang L, Shi Y, Zheng L, et al. Interleukin 12B rs3212227 T > G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. Dis Esophagus. 2015;28(3):291–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Tao YP, Wang WL, Li SY, Zhang J, Shi QZ, Zhao F, et al. Associations between polymorphisms in IL-12A, IL-12B, IL-12Rbeta1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J Cancer Res Clin Oncol. 2012;138(11):1891–900.CrossRefPubMedGoogle Scholar
  30. 30.
    Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer. 2005;103(4):740–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011;128(7):1692–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Huang ZQ, Wang JL, Pan GG, Wei YS. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin Biochem. 2012;45(1-2):54–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Miteva L, Stanilov N, Deliysky T, Mintchev N, Stanilova S. Association of polymorphisms in regulatory regions of interleukin-12p40 gene and cytokine serum level with colorectal cancer. Cancer Invest. 2009;27(9):924–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee KM, Shen M, Chapman RS, Yeager M, Welch R, He X, et al. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei. China Carcinogenesis. 2007;28(7):1437–41.CrossRefPubMedGoogle Scholar
  35. 35.
    Ebadi N, Jahed M, Mivehchi M, Majidizadeh T, Asgary M, Hosseini SA. Interleukin-12 and interleukin-6 gene polymorphisms and risk of bladder cancer in the Iranian population. Asian Pac J Cancer Prev. 2014;15(18):7869–73.CrossRefPubMedGoogle Scholar
  36. 36.
    Kaarvatn MH, Vrbanec J, Kulic A, Knezevic J, Petricevic B, Balen S, et al. Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development. Scand J Immunol. 2012;76(3):329–35.CrossRefPubMedGoogle Scholar
  37. 37.
    Wang J, Nong L, Wei Y, Qin S, Zhou Y, Tang Y. Association of interleukin-12 polymorphisms and serum IL-12p40 levels with osteosarcoma risk. DNA Cell Biol. 2013;32(10):605–10.CrossRefPubMedGoogle Scholar
  38. 38.
    Sima X, Xu J, Li Q, Luo L, Liu J, You C. Gene-gene interactions between interleukin-12A and interleukin-12B with the risk of brain tumor. DNA Cell Biol. 2012;31(2):219–23.CrossRefPubMedGoogle Scholar
  39. 39.
    Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2014;35(1):831–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394(3):415–20.CrossRefPubMedGoogle Scholar
  41. 41.
    Li L, Pan X, Li Z, Bai P, Jin H, Wang T, et al. Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Hum Immunol. 2013;74(8):993–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Li LJ, Pan XM, Sima X, Li ZH, Zhang LS, Sun H, et al. Interactions of interleukin-12A and interleukin-12B polymorphisms on the risk of intracranial aneurysm. Mol Biol Rep. 2012;39(12):11217–23.CrossRefPubMedGoogle Scholar
  43. 43.
    Yuzhalin AE, Kutikhin AG. Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors. 2012;30(3):176–91.CrossRefPubMedGoogle Scholar
  44. 44.
    Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol. 1997;159(1):28–35.PubMedGoogle Scholar
  45. 45.
    Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–46.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Immunology, West China School of Preclinical and Forensic MedicineSichuan UniversityChengduPeople’s Republic of China
  2. 2.Central LaboratoryYunnan University of Chinese Traditional MedicineKunmingPeople’s Republic of China
  3. 3.Department of Orthopedics, National Clinical Key Specialty, Yanan HospitalKunming Medical UniversityKunmingPeople’s Republic of China
  4. 4.Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children’s Health, West China Second University HospitalSichuan UniversityChengduPeople’s Republic of China
  5. 5.Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University HospitalSichuan UniversityChengduPeople’s Republic of China
  6. 6.Department of Forensic Biology, West China School of Preclinical and Forensic MedicineSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations